Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.42 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.41 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B known ✓ | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C known ✓ | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4260638 | 1.00 | PRSS1 (0.45) | PRSS1PRSS2PRSS3CES2CES1 | |
| Hydrochloric Acid SCHEMBL8687794 | 1.00 | PRSS1 (0.45) | PRSS1PRSS2PRSS3CES2CES1 | |
| Hydrochloric Acid SCHEMBL4260630 | 1.00 | PRSS1 (0.45) | PRSS1PRSS2PRSS3CES2CES1 | |
| Hydrochloric Acid SCHEMBL4260634 | 1.00 | PRSS1 (0.45) | PRSS1PRSS2PRSS3CES2CES1 | |
| Hydrochloric Acid SCHEMBL670430 | 1.00 | PRSS1 (0.45) | PRSS1PRSS2PRSS3CES2CES1 | |
| SCHEMBL6866945 | 0.99 | PRSS1 (0.46) | PRSS1PRSS2PRSS3CES2CES1 | |
| SCHEMBL752474 | 0.99 | PRSS1 (0.46) | PRSS1PRSS2PRSS3CES2CES1 | |
| SCHEMBL3265873 | 0.99 | PRSS1 (0.46) | PRSS1PRSS2PRSS3CES2CES1 | |
| SCHEMBL3265911 | 0.99 | PRSS1 (0.46) | PRSS1PRSS2PRSS3CES2CES1 | |
| SCHEMBL2322090 | 0.99 | PRSS1 (0.46) | PRSS1PRSS2PRSS3CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663456-B2 | Intermediate of tapentadol | SUN PHARMA ADVANCED RESEARCH COMPANY (IN) | 2017-05-30 | — | — | US | disclosed |
| US-20160264521-A1 | NOVEL INTERMEDIATE OF TAPENTADOL | SUN PHARMA ADVANCED RESEARCH COMPANY (IN) | 2016-09-15 | — | — | US | disclosed |
| EP-3063125-A1 | NOVEL INTERMEDIATE OF TAPENTADOL | Sun Pharma Advanced Research Company (IN) | 2016-09-07 | — | — | EP | disclosed |
| EP-2606030-B1 | PROCESS FOR THE PREPARATION OF TAPENTADOL | INDOCO REMEDIES LTD (IN) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015075744-A1 | NOVEL INTERMEDIATE OF TAPENTADOL | SUN PHARMA ADVANCED RESEARCH COMPANY (IN) | 2015-05-28 | — | — | WO | disclosed |
| US-8853456-B2 | Process for the preparation of tapentadol | INDOCO REMEDIES LIMITED (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2782917-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | Cancer Research Technology Limited (GB) | 2014-10-01 | — | — | EP | disclosed |
| WO-2013105109-A1 | PROCESS FOR THE PREPARATION OF TAPENTADOL | INDOCO REMEDIES LIMITED (IN) | 2013-07-18 | — | — | WO | disclosed |
| EP-2606030-A1 | PROCESS FOR THE PREPARATION OF TAPENTADOL | Indoco Remedies Limited (IN) | 2013-06-26 | — | — | EP | disclosed |
| WO-2013078126-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-05-30 | — | — | WO | disclosed |
| US-20130137890-A1 | PROCESS FOR THE PREPARATION OF TAPENTADOL | INDOCO REMEDIES LIMITED (IN) | 2013-05-30 | — | — | US | disclosed |
| WO-2012023147-A1 | PROCESS FOR THE PREPARATION OF TAPENTADOL | INDOCO REMEDIES LIMITED (IN) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264521-A1 | NOVEL INTERMEDIATE OF TAPENTADOL | OPRD1, OPRK1, OPRM1 | PARP1 4474/4885SLC6A2 275/4885SLC6A4 317/4885 |
| US-20130137890-A1 | PROCESS FOR THE PREPARATION OF TAPENTADOL | OPRD1, OPRM1, OPRK1 | PARP1 4101/4885SLC6A2 350/4885SLC6A4 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.